Introduction
Late infantile neuronal ceroid lipofuscinosis (LINCL) is an autosomal recessive, neurodegenerative lysosomal storage disease. [1] [2] [3] Mutations in the CLN2 gene result in a deficiency in the lysosomal activity of tripeptidyl peptidase I (TPP-I), with consequent accumulation of autofluorescent material resembling lipofuscin in the lysosomes. 4, 5 This storage material consists of undegraded proteins, primarily subunit c of mitochondrial ATP synthase. [6] [7] [8] Although all tissues of individuals with LINCL are TPP-I deficient, retinal pigmented epithelial cells and central nervous system (CNS) neurons are the most sensitive to decreased activity of TPP-I, resulting in their progressive destruction. 2, 3, 9, 10 The consequences are progressive loss of vision and neurological decline beginning at about age 3 years with cognitive impairment, seizures, and deteriorating motor skills that lead to a vegetative state and death in middle to late childhood. [1] [2] [3] There are compelling data to suggest that direct CNS administration of an adeno-associated virus (AAV) vector expressing the CLN2 cDNA should be able to mediate expression of TPP-I in a sufficient number of neurons to slow down, and potentially halt, the progression of the CNS disease. First, AAV gene transfer vectors are capable of mediating transfer and persistence of expression of a variety of genes in the CNS. [11] [12] [13] [14] [15] [16] [17] Second, mucopolysaccharidosis VII, a related lysosomal storage disease, has been successfully reversed in a knockout mouse model by recombinant AAV2-mediated intracranial gene transfer. 16, [18] [19] [20] Third, a significant fraction of newly synthesized TPP-I protein is secreted as pro-TPP-I, a 563 amino-acid inactive form which can crosscorrect nearby nontransduced cells through mannose 6-phosphate receptor-mediated uptake and subsequent activation in lysosomes to the 367 amino-acid mature form. 21, 22 This cross-correction between transduced cells and neighboring cells suggests that it will not be necessary to transfer the normal CLN2 cDNA to all the cells in the CNS, thus extending the effective range of gene transfer to broader regions of the brain. 17 Finally, comparisons of genotype and phenotype of children with CLN2 mutations reveal that expression as low as 5% of normal TPP-I levels lead to a much milder form of the disease with a delayed age of onset, less severe symptoms, and a prolonged lifespan, suggesting that this level of enzyme activity is a reasonable target for therapy. 23 This target level of expression of the transferred cDNA is within levels that could be achieved with current AAV vector technology.
There are several challenges to the development of AAV-mediated CLN2 therapy for LINCL. The CNS manifestations of LINCL are diffuse, and thus successful gene therapy will need to provide TPP-I activity over as broad a volume of the brain as possible.
1,2 Second, the absence of an experimental animal model for the disease until very recently 24 required that the detection of gene transfer-mediated TPP-I expression is above the background corresponding to normal expression in a naive animal. However, the target level for therapy is only 5% of the endogenous level and the various detection methods for TPP-I are not sensitive enough to detect this amount above the background. Finally, as with most genetic diseases, the optimal therapy would be to produce long-term expression of the therapeutic gene from a single administration of the vector.
Based on these considerations, this study is focused on assessment of CNS expression of TPP-I mediated by direct CNS administration of AAV2 CU hCLN2, an AAV serotype 2-based gene therapy vector applicable to treating LINCL. Direct CNS administration of AAV2-CU hCLN2 to rats and African green monkeys resulted in relatively stable and long-lasting expression of TPP-I within the CNS, which is promising for the development of gene therapy for LINCL.
Results

Function of AAV vectors in vitro
Cells infected with AAV2 CU hCLN2 were evaluated for TPP-I expression using both immunoperoxidase and immunofluorescence detection systems using a mouse monoclonal anti-human TPP-I antibody. Vector-mediated expression of TPP-I was evident using both immunoperoxidase and immunofluorescence detection (Figure 1a 10 pu) or AAV2GFP (10 10 pu, a control AAV2 vector with a GFP transgene). After 48 h, the medium was collected, the pro-TPP-I was converted to active TPP-I at low pH and TPP-I activity was assessed. The time course of increase in fluorescence is shown for various conditions. -mediated TPP-I expression were obtained with  cells infected with AAV2 CU rCLN2 (not shown) .
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Use of a TPP-I specific fluorogenic substrate showed that infection of cells by AAV expressing CLN2 resulted in TPP-I enzymatic activity in the cells with secretion into the media (Figure 1e ). The background activity in the media from uninfected cells was o10 fluorescence units (FU)/min-ml with o10 FU/min-mg in the cell homogenate. As expected, TPP-I activity was dose-dependent with infection by 4 Â 10 3 particle units (PU)/cell (4 Â 10 9 pu total dose) of AAV CU hCLN2 resulting in the secretion of 1.2570.24 Â 10 5 FU/min-ml, while infection by 4 Â 10 4 pu/cell (4 Â 10 10 pu total dose) gave 970.6 Â 10 5 FU/min-ml. The percentage of the total TPP-I activity in the media (as opposed to the cell-associated TPP-I activity) was 5.772% at 4 Â 10 3 pu/cell and 22.377% at 4 Â 10 4 pu/cell. Similar results of vector-mediated TPP-I activity were obtained with cells infected with AAV2-CU rCLN2 (not shown). Vector-derived TPP-I activity was demonstrated by lack of activity in controls including the assay of naive cells and cells transduced with comparable vectors with irrelevant transgene (AAV2GFP). The specificity of the assay for TPP-I activity was confirmed by inhibition using the TPP-I-specific enzyme inhibitor, Ala-Ala-Phe-chloro-methyl ketone.
In vitro cross-correction of LINCL-deficient fibroblasts mediated by AAV2 CU hCLN2
Like some other lysosomal storage disorders, LINCL is an attractive candidate for gene therapy due to crosscorrection, where a portion of the newly synthesized pro-TPP-I made by transduced cells may be taken up by neighboring cells, thereby amplifying the number of cells with TPP-I activity. This pathway was demonstrated in vitro by showing transfer of TPP-I from the media of cells infected with AAV2 CU hCLN2 to fibroblasts derived from an LINCL patient. The specificity of the transfer was indicated by the inhibition observed on addition of 1 mM mannose-6-phosphate (an inhibitor of uptake mediated by mannose-6-phosphate-mediated endocytosis), which reduced uptake by the LINCL fibroblasts by 78% (Figure 2 ). To ensure that the TPP-I activity in fibroblasts was not due to carry over of vector, AAV2 CU hCLN2 levels were assessed in the media transferred to the LINCL fibroblasts. The level was o1% of the input level of vector. In a separate experiment, when this level of AAV2 CU hCLN2 was used to infect LINCL fibroblasts, it did not yield a level of TPP-I activity over the background TPP-I activity following exposure of LINCL fibroblasts to media from naive 293ORF6 cells.
TPP-I distribution following AAV2-mediated CLN2 delivery to the rat brain Histological analyses and enzyme activity assays were used to determine the level, duration, and distribution of TPP-I expression that could be obtained by AAV2-mediated gene transfer in rat brain. Results obtained from transfer of the rat CLN2 gene (observed using the rabbit anti-TPP-I antibody) were indistinguishable from transfer of the human CLN2 gene (observed using the monoclonal anti-human TPP-I antibody). Results for both rat and human CLN2 gene delivered by AAV2-based vectors expression are described below.
TPP-I enzymatic activity assays were carried out on tissue homogenates of coronal sections of the brain of naive, AAV2 CU Null and AAV2 CU rCLN2-injected rats ( Figure 3) . The TPP-I activity of the sections of the uninjected right striatum was similar across the brain with no significant difference between the AAV2 CU Null and AAV2 CU rCLN2 group (P40.25 all locations). However, in the injected hemisphere, in the slice corresponding to the injection site, there was a significantly higher TPP-I activity in the AAV2 CU rCLN2-injected mice (Po0.05 compared to AAV2 CU Null group). The mean TPP-I activity (n ¼ 3 animals/group) was 55% greater than the background for this region. No significant differences were observed among the groups at any other location of the injected hemisphere (P40.05).
The striatum was chosen as a delivery site for its relatively homogeneous cellular architecture and large volume relative to the rat brain as a whole. Immunohistochemical examination of TPP-I expression at 4 weeks following a single striatal injection of 10 10 pu of AAV2 CU rCLN2 demonstrated robust TPP-I expression and the neuron-specific tropism of the AAV2-mediated gene delivery. The majority of striatal neurons in the injection region were found to express TPP-I, as determined by coexpression with NeuN, a marker for mature neurons (Figure 4 ). In contrast, adjacent GFAP-positive astrocytes did not contain detectable levels of TPP-I, nor were other TPP-I-positive/NeuN-negative cells observed by confocal microscopic analysis when registered focal plane series were evaluated for coexpression of cytoplasmic TPP-I and nuclear NeuN expression. Endogenous TPP-I gene expression was not observed at the dilution of the rabbit anti-TPP-I antibody used in this assay.
The TPP-I expression studies were not formal toxicology studies and did not use vector prepared within the requirements of Good Laboratory Practice. However, there was no observed behavioral difference between the AAV2 CU hCLN2-injected animals and the naive In vitro cross-correction of LINCL-deficient fibroblasts mediated by AAV2 CU hCLN2. Duplicate wells of 293ORF6 cells (10 6 ) were infected with AAV2 CU hCLN2 or AAV2 CU Null at 3 Â 10 4 pu/cell or mock infected. After 24 h, the medium was removed, the cells washed twice with PBS and replaced with RPMI media which was collected after a further 72 h. This medium was collected diluted 1:3, and placed onto LINCL-deficient fibroblasts in the presence or absence of 1 mM mannose-6-phosphate. After 24 h, the fibroblasts were collected, lysed, and assayed for TPP-I activity using a fluorometric assay. The means and standard deviation of quadruplicates is shown. * ¼ not detectable. Figure 3 Spatial distribution of TPP-I enzymatic activity following stereotactic injection of AAV2 CU rCLN2. Three rats were injected with 5 ml of AAV2 CU rCLN2 containing 5 Â 10 9 pu into the left striatum, and as controls three rats were injected with 5 ml of AAV2 CU Null containing 5 Â 10 9 pu into the left striatum. After 4 weeks, the animals were killed and the fresh brain was excised from the six treated and from two age-matched naive (untreated) animals. Each brain was divided into nine sections of 2 mm width by coronal sectioning. Each section was then divided into left and right hemispheres and the cortex was discarded leaving the internal structures (including the striatum). Sections were separated and homogenized. The TPP-I activity was determined and normalized to protein concentration of homogenate. The plots show the spatial distribution along the rostral/caudal axis for the TPP-I activity. The vertical arrow shows the estimated location of vector administration. The section for which the TPP-I activity of three AAV2 CU rCLN2-injected and three AAV CU 2Null-injected animals differ (Po0.05) is shown with an asterisk. The pathology of LINCL is diffuse throughout the CNS. To establish that the cellular expression of TPP-I could be observed following delivery to CNS locations other than the striatum, injections of AAV2 CU rCLN2 were made into several brain structures including the frontal cortex, the parietal cortex ( Figure 5 ), and the cerebellum (not shown). Examination of these regions 4 weeks following delivery confirmed TPP-I expression and neurotropism of AAV2 infection with TPP-I expression seen in neuronal populations in all regions. TPP-I expression was widespread in the cortical injection regions with neurons of both pyramidal and interneuron morphologies showing TPP-I expression. There was no observed TPP-I expression in astrocytes.
As a goal of the study was to obtain stable and longterm expression of the TPP-I transgene, the histology of striatal TPP-I expression was examined at intervals from 2 weeks to 18 months following injection of AAV2 CU hCLN2 ( Figure 6 ). Transgene expression from AAV2 vectors is known to increase gradually over several weeks and to persist for months or years. [25] [26] [27] Consistent with this, at 2 weeks postinjection, there was little detectable human TPP-I protein in the rat striatum, but by 1 month, abundant human TPP-I protein was observed. The high level, stable AAV2-mediated expression of human TPP-I in the rat striatum persisted at comparable volume and intensity at 4, 8, 12, and 18 months ( Figure 5 ). Quantitative assessment of TPP-I expression is a challenge because of the difficulties in standardizing the anti-TPP-I staining process, including the different reagent solutions used over time, and the differences in optimal immunostaining in the brains of rats from different ages. With this caveat, the Cavalieri estimator was used to quantify the TPP-I detected by immunostaining in the striatum over time ( Table 1) . The volume of cellular TPP-I expression expressed as a percentage of the striatum was variable ranging from 22 to 67% of the striatum at different time points. There was no correlation of average volume and time (P40.7 by linear regression).
As has been observed with AAV2 vectors expressing other transgenes, 28, 29 we observed a high level of TPP-I expression in cell populations not directly at the site of injection, but whose axonal projections were located in the site of the injection. As widespread delivery of the gene product throughout the brain is a goal of the current study, we examined other brain regions that project to the striatum to determine if expression of TPP-I could be detected in projection neuronal populations following single intrastriatal administration of AAV2 CU hCLN2. Interestingly, neurons in the cerebral cortex showed TPP-I expression as early as 2 months following delivery, and expression was more widespread at 4 and 8 months relative to the earlier time points ( Figure 7 ). By 8 months, TPP-I expression was also observed outside of the striatal injection area in neuronal populations in the thalamus and substantia nigra. Continued detection of TPP-I in neurons in these regions was observed at 12 months (not shown) and 18 months. In addition, at 18 months, TPP-I-positive cells were also Table 1 ). There was no correlation of the TPP-I-positive volume calculated as a % of the total hemisphere with time ranging from 1 to 18 months (P40.8).
TPP-I distribution after AAV2 CU hCLN2 administration to the non-human primate brain Expression of hCLN2 mediated by AAV2 delivery to the CNS was also observed in the brains of African green monkeys following injection of AAV2 CU hCLN2 ( Figures  8 and 9 ). Detectable levels of TPP-I expression were observed using human-specific monoclonal antibody via immunoperoxidase staining. The morphology of TPP-Ipositive cells in the cortex suggested that by 5 weeks both interneurons and pyramidal neurons expressed TPP-I, while staining in the caudate nucleus showed expression in cells with the morphology of interneurons ( Figure 8 ). Delivery to the hippocampus resulted in TPP-I expression in large multipolar hilar cells and, to a lesser extent, in dentate granule cells ( Figure 9 ). Thus, successful expression of AAV2-mediated delivery of TPP-I in the non-human primate brain was not region dependent. The identity of TPP-I-expressing cells was revealed by multiple immunofluorescence staining using the TPP-I human-specific monoclonal antibody. To discriminate between true signal and the contribution of autofluorescence (predominantly seen at the shorter wavelengths in non-human primate brain tissue), detection of TPP-I was accomplished with secondary antibodies conjugated to the fluorophore Cy5, that, upon far red spectral excitation, emits at infrared wavelengths. Consistent with delivery to the rat brain, examination of TPP-I-expressing cells in the non-human primate brain by multiple immunofluorescence staining revealed that neuronal, but not glial, populations were infected at all injection sites (Figures 8 and 9 ). Persistence of expression is a key factor for developing therapies for disorders such as LINCL. To evaluate duration of TPP-I expression in the non-human primate brain, animals were assessed at 5 and 13 weeks and found to contain equivalent distribution of TPP-I- (Figure 9 ). As with the rats, other than minor physical damage along the area of injection, there were no signs of inflammatory cell infiltration or vascular cuffing.
Discussion
LINCL is a fatal childhood disease with no known therapy. Several features of LINCL make it a good 
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D Sondhi et al candidate for gene therapy, including the monogenetic nature of the disease, knowledge of the deficient TPP-I protein and the gene (CLN2) that encodes it, a need for only low target levels of the therapeutic protein, and the ability of this protein to be secreted and internalized into neighboring cells providing potential for cross-correction. 4, 21, 23, 30 In regard to technologies available today, gene therapy is the best option for this disorder to protect neural cells from death. The present study describes the successful delivery and long-term expression of CLN2 by an AAV2-based vector, and the assessment of its gene product, TPP-I, following delivery to rat and non-human primate brain. The data fulfills three critical requirements for the preclinical development of therapy for this disease: (1) long term duration of expression of the therapeutic protein; (2) broad distribution of the therapeutic protein which may be a composite of infection and cross-correction; and (3) achieving sufficient levels of expression of the protein that should have therapeutic effect.
Duration
For the treatment of a chronic metabolic disorder such as LINCL, it is necessary to achieve long-term expression of TPP-I in the CNS. In this respect, the choice of vector is critical. In agreement with other reports, [31] [32] [33] [34] we have shown that an AAV2-based vector can maintain expression of the transgene and hence of the therapeutic protein for 41 year. In addition to the choice of vector, the choice of promoter is also critical for long-term high 
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level expression, as some viral promoters have been linked to premature decline of transgene expression. 35, 36 In the present study, we utilized the CMV-enhanced chicken b-actin promoter with the b-actin/rabbit b-globin hybrid intron, a promoter/intron combination that has been shown to successfully drive the expression of an AAV vector-mediated transfer of a gene in the brain for 41 year. 16 The combination of the long-term expressing vector AAV2 and a strong nonviral promoter led to robust TPP-I expression in the brain of rats for 418 months and for at least 3 months (the longest time period examined to date) in the brains of non-human primates in the present study. Owing to resources needed, there is limited data on long-term transgene expression in nonhuman primates beyond 90 days as described here, although one report shows persistent expression up to 134 days. 13 In rats, after 1 month, although there was variability, there was no significant time-dependent change in the extent of transgene expression following AAV2 CU hCLN2 gene transfer as assessed by the TPP-I- 
TPP-I distribution
Robust transduction of neurons was achieved following administration of the AAV2 CU hCLN2 vector to the rat and non-human primate brain. The neurotropic specificity of AAV2-based vectors has been previously observed with AAV2-mediated gene delivery. 11, 37, 38 The neurotropism of AAV2 makes this vector suitable for use as a gene delivery vehicle for neurons, the target cell population for intervention in LINCL. 2, 9 In the rat, a single intrastriatal injection resulted in histological detection of TPP-I throughout both dorsal and ventral extents of the striatum. The extent of TPP-I expression encompassing, nearly half of the striatum, remained stable over time following gene delivery.
Of interest relevant to the goal of achieving widespread expression of TPP-I in the CNS was the observation in the rat that distant neurons expressed TPP-I after a lengthy interval following delivery. The distribution of these sites of extrastriatal TPP-I expression was highly variable over time but consistent with the known circuitry of striatal projections. Neurons in both the dorsal and ventral striatum receive input from cerebral cortex, thalamus, and the midbrain ventral tegmental area and substantia nigra. [39] [40] [41] Thus, distant neurons, whose axons terminate in the region of vector delivery, were able over time to express TPP-I. There are two possible explanations for TPP-I expression in distant projection neurons. Previous reports have demonstrated that distant neurons can be transduced by retrograde transport of the viral vector following AAV2 delivery to the CNS. 28 Alternatively, the secreted TPP-I enzyme could be taken up by synaptic terminals and undergo retrograde transport to distant cell bodies. This mechanism would be consistent with the in vitro cross-correction data showing that TPP-I is secreted by cells transduced by AAV2 CU hCLN2 and subsequently taken up by nontransduced cells in a mannose-6-phosphate-dependent pathway. It would also be consistent with the extensive intracellular staining for TPP-I observed in transfected cells, where TPP-I was likely present in all compartments of the secretory and endocytic pathways. Whatever the mechanism of this retrograde expression, these results suggest that it may be possible to utilize the circuitry of neuronal connections to extend the effective expression of TPP-I to distant regions. This possibility greatly augments the therapeutic potential of each intracerebral injection and suggests that the circuitry of the brain should be taken into account when designing therapeutic delivery.
In a careful survey of sections of the brains of the AAV2 CU hCLN2 non-human primates, no TPP-I-positive cells far from the injection site suggestive of retrograde transport were seen. There may be two reasons for this. First, the retrograde transport observed in rats increased over time with a maximum at 8 months and monkeys were assessed at shorter time points due to resource limitations. Second, the sensitivity of the immunohistochemistry in the non-human primates was titrated down by use of lower levels of the monoclonal anti-TPP-I antibody than that used in the rats (1:15 000 as compared to 1:1000). This was done to suppress the endogenous TPP-I background in the non-human primate tissue but this also reduces the sensitivity with which retrograde transport may be seen.
TPP-I protein levels
At present, there is no defined clinical benchmark for the minimum level of TPP-I expression required for successful therapeutic intervention for LINCL. Individuals who are heterozygous for LINCL have no disease phenotype suggesting that it will not be necessary to completely restore normal TPP-I levels. [1] [2] [3] Furthermore, individuals with LINCL who have a mutation in CLN2 that results in 5-10% of normal TPP-I activity have delayed onset of the symptoms, 23 suggesting that as little as 5% of normal activity spread throughout the brain represents a reasonable target level for clinical benefit.
While a target of 5% of normal levels makes the goal of effective therapy for LINCL easier to achieve with gene therapy, the available analytical methods are not sufficiently sensitive to demonstrate an increase in only 5% over a background of normal TPP-I levels in vivo. For example, the variance in the TPP-I activity measurement on brain homogenates of naive rats was 24%, a value much greater than the target level. However, a TPP-I level was obtained that was 55% above background following AAV2 CU hCLN2 infection demonstrating that locally therapeutic levels are easily achieved. As no characterized TPP-I-deficient animal model is available, we are only able to evaluate TPP-I levels that are significantly increased over the background. There is a wide distribution of robust TPP-I-positive cells detected following AAV2-mediated gene delivery using immunohistochemistry under conditions that gave no signal for endogenous TPP-I. Although immunohistochemical staining does not allow for a linear quantitative estimation of protein levels, this technique is also not particularly sensitive to very low intracellular protein levels. Thus, immunohistochemical detection likely underestimates the true extent of CLN2 gene product expression, suggesting that at least the minimum target levels of TPP-I expression have been achieved in the identified regions.
Implications for future studies
This study supports the notion that AAV2-mediated CLN2 gene delivery to the CNS can meet the criteria of widespread, robust transgene expression of long duration required for the development of a therapeutic gene delivery strategy. The recent characterization of a CLN2-deficient mouse, 24 which displays a similar pathology as LINCL in humans will also allow the potential therapeutic benefit of intracranial gene transfer to be assessed more rigorously. There is currently favorable short-term safety data related to the intracranial transfer of AAV2 CU hCLN2 in human patients based upon the growing clinical experience of AAV2-mediated gene transfer to the brain for the treatment of Canavan and Parkinson's diseases. 42, 43 Therefore, it seems likely that there would be no significant safety issues related to intracranial transfer of AAV2 CU hCLN2 in human patients. In this context, LINCL is a candidate disease for further preclinical development of AAV2-mediated gene therapy.
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Methods
Production of AAV2 vectors
The overall genome structure of all AAV vectors used in the study included (5 0 -3 0 ): the 141 nt inverted terminal repeat (ITR) from AAV2; an expression cassette that included the CAG promotor (the human cytomegalovirus immediate/early enhancer; the promoter, the splice donor, and the left-hand intron sequence from chicken b-actin; the right-hand intron sequence and splice acceptor from rabbit b-globin);
44-46 the cDNA of interest with an optimized Kozak consensus translation initiation signal prior to the start codon; the rabbit b-globin poly A/stop sequence; and the 141 nt ITR. The vectors were produced using two plasmids: (1) 'AAV2-ITR/expression' plasmid containing (5 0 -3 0 ): the AAV2 ITR, CAG promoter, the cDNA of interest, the polyA/stop, and the AAV ITR; and (2) adenovirus/AAV helper gene plasmid (pPAK-MA2) containing (5 0 -3 0 ): the mouse mammary tumor virus ITR promoter driving the AAV2 rep gene, followed by the AAV2 cap gene and the adenovirus serotype 5 VA, E2, and E4 genes, each driven by their own promoter. 47, 48 The AAV2 vectors used in the study included: AAV2 CU hCLN2 (expression cassette includes the human CLN2 cDNA); AAV2 CU rCLN2 (identical to AAV2 CUhCLN2 except that it has the rat CLN2 cDNA substituted for the human CLN2 cDNA); and AAV2 CU Null (used as a control, identical to AAV2 CU hCLN2 except that it has an untranslatable DNA sequence corresponding to intron 5 of the human vascular endothelial growth factor gene to match the size of the human CLN2 cDNA); and AAV2GFP used as a negative control (see Zolotukhin et al 49 for a description of AAV2GFP). All of the AAV2 vectors were produced in the same manner using Polyfectt (QIAGEN Sciences, Germantown, MD, USA) mediated cotransfection of 500 mg of the expression cassette plasmid containing the transgene of interest and 1 mg of the AAV/adenovirus helper gene plasmid into a 10 Stack Cell Factory (NUNCt Brand Products, VWR Scientific, West Chester, PA, USA) at 70% confluence of low passage 293 cells. Post transfection (72 h), the cells were harvested and a crude viral lysate made by three cycles of freeze/thaw, then clarified by centrifugation and purified by discontinuous iodixanol gradients and heparin agarose chromatography. 50 All vectors were assessed by quantitative PCR (TaqMan), capsid ELISA (Research Diagnostics, Flanders, NJ, USA), and by their ability to replicate in adenovirusinfected C12 cells (a cell line expressing the AAV2 rep and cap genes) with detection of the amplified genome by DNA hybridization. 51 Evidence that the CLN2 vectors could direct the expression of the desired transgene product was established by assessing TPP-I enzyme activity (as described below). For the in vitro and in vivo experiments, all vectors were dosed on the basis of particle units as assessed by ELISA (Research Diagnostic Inc., Flanders, NJ, USA).
Morphological evaluation of TPP-I protein expression in vitro
The AAV2 CU hCLN2 vector was evaluated for its ability to produce TPP-I by indirect immunofluorescence and immunoperoxidase detection of CLN2 expression.
293ORF6 cells, from a human embryonic kidney cell line expressing adenovirus E1 and E4 genes 52 were maintained in Dulbecco's modified Eagle's medium (DMEM, Invitrogen Life Technologies, Carlsbad, CA, USA) supplemented with 1 mM sodium pyruvate, 10% fetal bovine serum (FBS), 50 U/ml penicillin, 50 mg/ml streptomycin, 2 mM L-glutamine, and 0.25 mg/ml fungizone-amphotericin. For the AAV expression studies, the 293ORF6 cells (5 Â 10 4 cells) were infected with AAV2 CU hCLN2 or AAV2 CU Null (10 3 particles/cell) in 30 ml serum-free DMEM at 371C. After 30 min, 2 ml of DMEM supplemented with 100 mM ZnCl 2 were added to the cells to activate the E4 gene expression. 52 After 2 days, the cells were washed twice with phosphate-buffered saline, pH 7.4 (PBS) and fixed with 4% paraformaldehyde (Electron Microscopy Sciences, Fort Washington, PA, USA) in PBS. For immunoperoxidase detection of TPP-I, the cells were then pretreated with 0.03% hydrogen peroxide (Sigma-Aldrich, St Louis, MO, USA) for 5 min, 221C to quench endogenous peroxidase activity. The cells were then treated (20 min, 221C) with blocking medium (5% goat serum, 1% bovine serum albumin (BSA), in PBS). Primary antibodies were diluted in blocking medium (1:100), including mouse anti-human CLN2 hybridoma supernatant (clone mAb 8C4, provided by Krystyna Wisniewski, Institute for Basic Research in Developmental Disabilities, Staten Island, NY, USA) and mouse anti-shiga toxin hybridoma supernatant as an irrelevant primary antibody control (clone 11F11, American Type Culture Collections, Manassas, VA, USA). The primary antibodies were applied for 60 min at 371C, removed with three 5 min washes with 1% BSA in PBS. Horseradish peroxidase-based immunochemistry was performed using the Envision kit (Dako, Carpinteria, CA, USA) according to the manufacturer's instructions. Briefly, horseradish peroxidase-conjugated secondary antibody (anti-mouse) was applied to cells for 30 min at 371C, washed three times in PBS, and treated with the diaminobenzidine-activator cocktail for 5 min at 221C. Cells were counterstained using hematoxylin (SigmaAldrich) and imaged using a Leaf MicroLumina color charge coupled device (CCD) camera (ElectroImage, Great Neck, NY, USA).
For immunofluorescence detection of TPP-I, the cells were infected and fixed as described above, and then, after three washes in PBS, cells were postfixed in 100% methanol (À201C, 20 min), and washed three times in PBS. The cells were then blocked and treated with primary antibodies as described above with the exception of hybridoma supernatants being diluted 1:10 instead of 1:100 and application at 221C instead of 371C. The primary antibodies were applied for 60 min and removed as described above and replaced with a secondary antibody for 45 min at 221C (dilution of 1:100 in blocking medium, goat anti-mouse Alexa 488, Molecular Probes, Eugene, OR, USA). The secondary antibody was removed with three 5 min washes with 1% BSA in PBS followed by three rinses in PBS. Nuclei were stained with 4 0 -6-diamidino-2-phenylindole (DAPI, 2 mg/ml in PBS, 5 min, 221C, Molecular Probes). Cells were observed using widefield epifluorescence microscopy using an Olympus IX70 microscope. Images were captured using a Photometrics Quantix cooled CCD camera and analyzed using MetaMorph image analysis program (Universal Imaging, Downingtown, PA, USA).
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Evaluation of TPP-I enzyme activity
The function of vector-derived TPP-I was demonstrated by assessing TPP-I enzyme activity using a fluorescentactivated specific substrate. In 24-well plates, 10 6 293ORF6 cells were incubated until 90% confluent and then infected (10 8 -10 10 pu) with AAV2 CU hCLN2, AAV2GFP (an irrelevant transgene control), or AAV2 CUNull. Medium was collected 48 h postinfection and transferred to a 96-well plate. The cells were harvested separately and suspended in 100 ml of 0.15 M NaCl, 0.1% Triton X-100 to make a lysate. Secreted enzyme in 10 ml of medum was activated with 20 ml of an activating solution (150 mM NaCl, 0.1 % Triton X-100, and 50 mM formic acid, pH 3.5) to mimic its natural activation in the lysosomes following reuptake. 21 After incubation at 371C for 30 min, 250 mM Ala-Ala-Phe-7-amido-4-methylcoumarin (the TPP-I-specific substrate; Sigma-Aldrich) in 40 ml of 150 mM NaCl, 0.1% Triton X-100, and 100 mM sodium acetate, pH 4.0 was added and a fluorescence (360/20 nm excitation, 460/25 emission) time course was then determined at 10 min intervals for 80 min at 371C in a Cytofluor 4000 TC plate reader (PerSeptive Biosystems, Foster City, CA, USA). 21 The activity of the vectorderived TPP-I was determined by calculating the change in FU per viral particle dose per min over a linear portion of the curve minus the corresponding activity in cells infected with a control vector encoding an irrelevant transgene. This assay provides an intrinsic specification for vector potency that can be applied independent of yield, a parameter that varies between different viral preparations. In this assay, vector preparations were accepted that gave 43 Â 10 À6 FU/(min-ml media-pu). To demonstrate specificity of the assay, it was performed in the presence and absence of a TPP-I-specific inhibitor, Ala-Ala-Phe-chloro-methyl ketone (1 mM, Sigma-Aldrich Co; see Lin and Lobel 21 and Ezki et al 53 ).
To assess the ability of AAV2 CU hCLN2 to direct the expression of a CLN2 product that will cross-correct neighboring cells, the medium of quadruplicate wells of 293ORF6 cells infected with 3 Â 10 4 pu/cell AAV2 CUhCLN2 or AAV2 CU Null was removed 24 h postinfection and the cells were washed twice with PBS. It was then replaced by fibroblast medium (RPMI 1640 media containing 1% glutamine, 10% FBS, 50 U/ml penicillin, 50 mg/ml streptomycin, 2 mM L-glutamine and 0.25 mg/ ml fungizone-amphotericin) for 72 h. This medium was collected and assessed for pro-TPP-I content by enzymatic assay, and for AAV2 CU hCLN2 content by Taqman. LINCL fibroblasts (provided by P Lobel, Robert Wood Johnson Medical College) were cultured in fibroblast medium until 70% confluent at which time 30% of the medium was replaced by the media collected from the 293ORF6 cells with or without 1 mM mannose-6-phosphate as a competitive inhibitor of uptake. After 24 h, the cells were harvested and lysed in 150 mM NaCl, 0.1% Triton X-100 for assessment of TPP-I activity.
To insure that the TPP-I activity in the LINCL fibroblasts did not result from carry over of AAV2 CUhCLN2 in the media from the 293ORF6 cells initially infected by the vector, carry over was assessed in the media using TaqMan real-time quantitative PCR with primers (forward: GTCAATGGGTGGAGTATTTACGG and reverse: AGGTCATGTACTGGGCATAATGC) and probe (CAAGTGTATCATATGCCAAGTACGCCCCCT) specific to the CMV enhancer. The amount of AAV2 CUhCLN2 determined to be carried over by this method was used to directly infect the LINCL fibroblasts with assessment of the TPP-I activity in the media after 72 h.
CNS administration of AAV2 vectors in rats
To evaluate TPP-I expression and distribution following AAV2-mediated CLN2 delivery in a small animal model brain, Fischer 344 male rats (180-200 g; Taconic, Germantown, NY, USA) were used with Institutional Animal Care and Use Committee (IACUC) approval of all procedures. The rats were deeply anesthetized and positioned in a stereotaxic frame for unilateral injection into the left striatum (AP +0.6 mm, ML +2.8 mm, and DV À5.2 mm relative to Bregma), frontal cortex (AP +3.0, ML +2.8, DV À2.5), parietal cortex (AP À1.3, ML +2.5, DV À2.0), or cerebellum (AP À10.0, ML 2.5, DV À3.7). The AAV vectors, formulated in PBS (1.0-5.0 ml per site), were injected at a rate of 0.2 ml/min using a microprocessorcontrolled infusion pump (Model 310, Stoelting, Wood Dale, IL, USA). The injection needle was left in position for 1 min prior to, and 2 min following delivery before being slowly withdrawn from the brain. Animals received either AAV2 CU rCLN2 (10 9 or 10 10 pu) or AAV2 CU hCLN2 (10 9 or 10 10 pu). Pilot experiments suggested that there was no effect of total injection volume (at constant vector dose) on the distribution or level of TPP-I under these conditions (not shown). Other animals received AAV2 CU Null (10 9 or 10 10 pu) or PBS to control for the specificity of transgene expression.
Enzymatic assay of TPP-I activity in brain homogenate
To assess TPP-I enzymatic activity in the brain of AAV2 CU CLN2-injected rats, vector injections were performed as described above, and at the relevant time, the animals were euthanized and the brains were harvested unfixed. The brains were rinsed in ice-cold PBS, placed in a rodent brain matrix, which was on ice (Electron Microscopy Sciences, Hatfield, PA, USA), and sliced into nine 2 mm coronal sections using matrix-specific razor blades. All sections were hemisected prior to analysis. Each half of the sections from the left hemisphere was further dissected into cortex and noncortex (striatum). Samples were stored at À801C in microcentrifuge tubes until used. TPP-I activity was assayed by homogenization of the brain tissue in blank solution (150 mM NaCl, 1 mg/ml Triton X-100) using a disposable pellet pestle and 1.5 ml matching tube (Kimble-Kontes, Vineland, NJ USA). The homogenate was clarified by centrifugation and the supernatant was transferred onto a 96-well plate and assayed for TPP-I activity as described above. The activity of the transgene product was determined by calculating the change in fluorescence units per min per mg of protein (standardized by BCA protein assay, Pierce Biotechnology, Rockford, IL, USA).
Morphological evaluation of TPP-I protein expression in the rat brain
To assess TPP-I distribution and tropism at various time points after CNS administration of the vectors, rats were deeply anesthetized and perfused transcardially with AAV-mediated CNS transfer of CLN2 D Sondhi et al ice-cold PBS followed by ice-cold 4% paraformaldehyde in 0.1 M phosphate buffer (200 ml each). The brains were then harvested and immersed in the same fixative overnight, equilibrated in 30% sucrose at 41C; serial 50 mm thick sagittal sections were later produced by freezing sliding microtomy.
Multiple immunofluorescence labeling was performed using antibodies specific for neurons (mouse anti-NeuN, 1:2500, Chemicon International, Temecula, CA, USA or mouse anti-calbindin, 1:5000, Swant, Bellinzona, Switzerland) or astrocytes (guinea pig anti-GFAP, 1:500, Advanced Immunochemical, Long Beach, CA, USA). Expression of the CLN2 transgene product was detected using antibodies against TPP-I. For specific detection of the human CLN2 transgene product, a mouse antihuman TPP-I antibody was used at a dilution of 1:1000. For detection of either human CLN2 or rat CLN2 transgene products, a rabbit anti-TPP-I antibody (provided by P Lobel, Robert Wood Johnson Medical College) was used at a dilution of 1:1000. When appropriate, sections were counterstained with the fluorescent nucleic acid dye, propidium iodide (1:5000 for 3 min; Molecular Probes). Propidium iodide labels all nuclei within the tissue section and acts as a 'fluorescent Nissl stain', permitting the phenotypic identity to cells to be established according to classic criteria used with Nissl staining. 54 Donkey secondary antibodies specific for relevant species were conjugated to biotin, Cy2, Cy3, or Cy5 or streptavidin-conjugated fluorophores (1:500; all from Jackson ImmunoResearch, West Grove, PA, USA) as appropriate for the specific discrimination of primary antibodies. Specificity of antibody detection was verified by staining uninfected tissue and by omission of primary antibodies in infected tissue. In separate sections, immunoperoxidase detection of the rat CLN2 transgene product was accomplished by quenching of endogenous peroxidase activity and incubation with rabbit anti-TPP-I polyclonal antibody (1:1000) or the human CLN2 transgene product by mouse anti-human TPP-I antibody (1:1000), followed by biotin-streptavidin amplification (Vectastain kit, Vector Laboratories, Burlingame, CA, USA) and visualization with a nickel chloride-enhanced diaminobenzidine reaction. Images were obtained by confocal microscopy (Olympus FluoView) for the immunofluorescence-stained material or brightfield images were obtained by digital image acquisition (Olympus BX50; Nikon D100) for the immunoperoxidase-stained material. Volume estimates of the extent of detectable TPP-I expression in the rat brain was carried out using the Cavalieri estimator on a one in six series of immunoperoxidase-stained sections through the entire hemisphere exclusive of the cerebellum, brainstem, and olfactory bulb. 55 Linear regression analysis was performed to assess volume changes over time.
CNS administration of AAV2 vectors in non-human primates
To evaluate TPP-I expression and distribution following AAV2-mediated CLN2 delivery in a large animal model brain, non-human primates were used. These studies were carried out at the St Kitts Biomedical Research Foundation, a facility that operates under Public Health Service regulations with IACUC oversight and with an assurance document filed at the National Institute of Health. African green monkeys (Chlorcebus aethiops sabaeus, male, 4.8-6.2 kg, feral, 5-10 years old) were deeply anesthetized and restrained in a stereotactic frame equipped with Hamilton microsyringes, which are controlled by a nano injector, stepper motorized injection pump (Stoelting Co., Wood Dale, IL, USA) for injection to 12 locations through six burr holes (two depths per burr hole), three per hemisphere of the AAV vector or diluent control. Injection coordinates for the prescribed brain structures in the African green monkey were determined from previously injected and sectioned brains and are translated to the stereotactic instrument frame of reference. Injections were made to the head of the caudate nucleus and overlying cerebral cortex (16.2 mm apart), body of the caudate nucleus and the overlying cerebral cortex (19.2 mm apart), and the hippocampal formation and overlying cerebral cortex (31.2 mm apart). Before and after each injection, the brain tissue was allowed to seal around the syringe needle. The vector or PBS was delivered at each site at 1 ml/min for a total volume of 180 ml (15 ml at each of 12 locations delivered over 15 min at each site). Each non-human primate received a total dose of 3.6 Â 10 11 pu of the AAV2 CU hCLN2 vector or 3.6 Â 10 11 pu of the control AAV2 CU Null vector or the diluent PBS.
Assessment of TPP-I expression in the non-human primate brain
To assess TPP-I distribution and tropism in the nonhuman primate CNS, at various time points after vector injection, the non-human primates were deeply anesthetized and transcardially perfused with cold PBS. The brains were immediately removed and kept on ice while uniform 4 mm coronal slabs were cut using a specially fabricated brain mold. The right hemisphere of each slab was placed in 4% paraformaldehyde for 3-7 days for immersion fixation prior to transfer to 30% sucrose. The left hemisphere of the slabs was saved for future analysis.
The 4 mm coronal slabs from the right hemisphere were further sectioned (50 mm slices) and used for immunoperoxidase detection and immunofluorescence in methods similar to that described for the rat tissue. However, to help to discriminate transgene product from endogenous protein, a 1:15 000 dilution of the primary monoclonal anti-TPP-I antibody was used for the nonhuman primate brain rather than the 1:1000 dilution used for sections of rat brain. To separate detection of TPP-I immunofluorescence from autofluorescence in non-human primate tissue, secondary antibodies were conjugated to Cy5, which fluoresces in the far red portion of the visible spectra. To maintain continuity to analysis of the rat tissue, signal detection of TPP-I was mapped to the green channel for image composition.
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